JSA Advised On Suven Pharma’s Merger With Cohance Lifesciences

May 15, 2025

JSA advised Advent International and Suven Pharmaceuticals Limited, in the ~USD 3 billion dollar (combined) merger of Cohance Lifesciences Limited with and into Suven Pharmaceuticals Limited, as one of the largest transactions of its kind. Following the merger, Suven Pharmaceuticals Limited has now been renamed as Cohance Lifesciences Limited.

The transaction team was led by Partner & National Corporate Lead Iqbal Khan & Partner Ambarish with support from Principal Associate Krishaal Morjaria, Senior Associate Tarini Sardesai along with Associates Ayushi Choudhary and Raviraj Zinzuvadia.

Ambarish, Ayushi Choudhary, Iqbal Khan, Krishaal Morjaria, Raviraj Zinzuvadia, Tarini Sardesai

Pharmaceuticals

Mergers & Acquisitions

The deal reporting on this platform is based on the information received from law firms, and therefore, some details may be missing/incomplete. If your firm has not been credited for this deal, write to us at connect@thedealmatter.com mentioning your firm’s name, lawyers involved (including designation) and client represented.